Laboratory‐based biomarkers to improve causality assessment in drug‐induced liver injury
Daniel J. Antoine – 1 March 2017
Interleukin‐6: The dark side of liver regeneration in chronic liver disease
Andreas Geier, Daniel Jahn, Heike M. Hermanns – 1 March 2017
Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis
Claudia D. Fuchs, Emina Halilbasic, Michael Trauner – 1 March 2017
The role of the hepatopathologist in the assessment of drug‐induced liver injury
David E. Kleiner – 1 March 2017
What can we learn from other clinical settings on the influence of the gut microbiome on the brain?
Eamonn M. M. Quigley – 1 March 2017
Overview of causality assessment in drug‐induced liver injury
Paul H. Hayashi – 1 March 2017
LiverLearning®: 2018 Webinar: Portal Vein Thrombosis in Cirrhosis: Causes and Consequences
This webinar will focus on the concept of coagulation in cirrhosis; pathophysiology, concept of a rebalanced coagulation state in cirrhosis and the consequences such as portal vein thrombosis. The management of PVT will be discussed.Andres Cardenas (Moderator) Dr. Andrés Cárdenas is currently a Consultant and Clinical Professor of the Institute of Digestive Diseases and Metabolism at Hospital Clinic and University of Barcelona.
The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice
Zhiwen Fan, Luyang Li, Min Li, Xinjian Zhang, Chenzhi Hao, Liming Yu, Sheng Zeng, Huihui Xu, Mingming Fang, Aiguo Shen, Thomas Jenuwein, Yong Xu – 28 February 2017 – Uncontrolled inflammatory response highlights the central theme of nonalcoholic steatohepatitis (NASH), a growing global pandemic. Hepatocytes and macrophages represent two major sources of hepatic inflammation during NASH pathogenesis, contributing to excessive synthesis of proinflammatory mediators. The epigenetic mechanism that accounts for the activation of hepatocytes and macrophages in this process remains obscure.